Immutep Stock Quote IMMP - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

1.92

Bid

1.93

Ask

1.98

Volume

182,074

1.8724 Day's Range 1.96

0.00 52 Week Range 0.00

Market Cap

279.277M

Previous Close

1.84

Open

1.92

Last Trade

1.979

Last Trade Time

Financial Volume

$ 351,384

VWAP

1.9299

Average Volume (3m)

Shares Outstanding

145,456,785

Dividend Yield

PE Ratio

-1.06

Earnings Per Share (EPS)

-0.29

Revenue

Net Profit

-42.72M

Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesse... Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's unique ability to stimulate or suppress the immune response. Immutep's lead clinical candidate, eftilagimod alpha ('efti'), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.immutep.com

Headquarters

Sydney, New South Wales, Aus

Founded

Immutep Ltd is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IMMP. The last closing price for Immutep was $1.84. Over the last year, Immutep shares have traded in a share price range of $ 0.00 to $ 0.00.

Immutep currently has 145,456,785 shares outstanding. The market capitalization of Immutep is $267.64 million. Immutep has a price to earnings ratio (PE ratio) of -1.06.

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma

Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society 2024 Annual MeetingEFTISARC-NEO is the first trial to...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Symbol	Price	Vol.
PDYNPalladyne AI Corporation	$ 4.59 (129.50%)	83M
QMCOQuantum Corporation	$ 9.11 (126.62%)	39.41M
NANano Labs Ltd	$ 8.26 (89.02%)	2.03M
XCURExicure Inc	$ 18.60 (71.27%)	4.36M
SKKSKK Holdings Limited	$ 1.75 (59.09%)	95.06M
AMIXAutonomix Medical Inc	$ 6.21 (-54.07%)	897.51k
CETXCemtrex Inc	$ 0.1146 (-41.74%)	22.89M
MSWMing Shing Group Holdings Ltd	5.90 (-35.52%)	417.08k
RMSGReal Messenger Corporation	$ 3.09 (-26.25%)	305.85k
ENSCEnsysce Biosciences Inc	$ 0.4414 (-25.49%)	3.93M
ELABElevai Labs Inc	$ 0.0201 (-0.50%)	425.38M
NVDANVIDIA Corporation	$ 141.95 (-3.22%)	236.51M
SMCISuper Micro Computer Inc	$ 33.15 (11.62%)	159.61M
VRPXVirpax Pharmaceuticals Inc	$ 0.5501 (-6.72%)	159.39M
SOUNSoundHound AI Inc	$ 8.24 (18.05%)	107.91M

Symbol

Price

Vol.